149 related articles for article (PubMed ID: 38863918)
1. Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Yanto TA; Budiputri CL; Muljono MP; Chandra S
J ASEAN Fed Endocr Soc; 2024; 39(1):95-105. PubMed ID: 38863918
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Liang W; Gao L; Li N; Wang B; Wang L; Wang Y; Yang H; You L; Hou J; Chen S; Zhu H; Jiang Y; Pan H
Horm Metab Res; 2015 Oct; 47(11):805-12. PubMed ID: 26332757
[TBL] [Abstract][Full Text] [Related]
3. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
[TBL] [Abstract][Full Text] [Related]
4. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Chamarthi B; Cincotta AH
Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
[TBL] [Abstract][Full Text] [Related]
5. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH
Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032
[TBL] [Abstract][Full Text] [Related]
6. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
[TBL] [Abstract][Full Text] [Related]
7. Quick-release bromocriptine for treatment of type 2 diabetes.
Mikhail N
Curr Drug Deliv; 2011 Sep; 8(5):511-6. PubMed ID: 21696353
[TBL] [Abstract][Full Text] [Related]
8. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
Roe ED; Chamarthi B; Raskin P
J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
Schwartz SS; Zangeneh F
Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
[TBL] [Abstract][Full Text] [Related]
10. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Lamos EM; Levitt DL; Munir KM
Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
[TBL] [Abstract][Full Text] [Related]
11. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
Gaziano JM; Cincotta AH; Vinik A; Blonde L; Bohannon N; Scranton R
J Am Heart Assoc; 2012 Oct; 1(5):e002279. PubMed ID: 23316290
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus.
Kerr JL; Timpe EM; Petkewicz KA
Ann Pharmacother; 2010 Nov; 44(11):1777-85. PubMed ID: 20978217
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
Gaziano JM; Cincotta AH; O'Connor CM; Ezrokhi M; Rutty D; Ma ZJ; Scranton RE
Diabetes Care; 2010 Jul; 33(7):1503-8. PubMed ID: 20332352
[TBL] [Abstract][Full Text] [Related]
14. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
15. Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
Siamashvili M; Davis S
Expert Opin Pharmacother; 2021 Feb; 22(2):241-247. PubMed ID: 33030357
[TBL] [Abstract][Full Text] [Related]
16. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.
Garber AJ; Blonde L; Bloomgarden ZT; Handelsman Y; Dagogo-Jack S
Endocr Pract; 2013; 19(1):100-6. PubMed ID: 23337160
[TBL] [Abstract][Full Text] [Related]
17. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
Scranton R; Cincotta A
Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
[TBL] [Abstract][Full Text] [Related]
20. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Asbaghi O; Fatemeh N; Mahnaz RK; Ehsan G; Elham E; Behzad N; Damoon AL; Amirmansour AN
Pharmacol Res; 2020 Nov; 161():105098. PubMed ID: 32730903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
